Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Follistatin 344

FS-344, Activin-Binding Protein, FST344

Quick Stats
Studies 2
Trials 73
Completed OBSERVATIONAL NCT04203212

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The investigators aim to investigate the effect of menstrual cessation in women with endometriosis treated with GnRH analogs for 6 months on bone mineral density and bone and muscle metabolism parameters and subsequently the effects of menstrual restoration after GnRH analogs discontinuation on the above measured parameters

Detailed Description

Prospective, open-label, controlled 12month observational study Premenopausal women with surgically verified endometriosis will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration. Age- and BMI-matched premenopausal, health women will serve as controls. Controls will receive no treatment.

Interventions

Name: Goserelin Acetate
Type: DRUG
Description: Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months

Primary Outcomes

Measure: lumbar spine BMD
TimeFrame: between baseline and 6 months after goserelin initiation
Description: Bone mineral density changes at the lumbar spine measured by dual-energy absorptiometry
Measure: lumbar spine BMD
TimeFrame: between baseline and 6 months after goserelin discontinuation
Description: Bone mineral density changes at the lumbar spine measured by dual-energy absorptiometry

Trial Information

NCT ID

NCT04203212

Status

Completed

Study Type

OBSERVATIONAL

Sponsor

424 General Military Hospital

Last Updated

December 15, 2025

Related Peptides